Demyelinating disorders of the central nervous system are among the most crippling neurological diseases affecting patients at various stages of life. In the most prominent demyelinating disease, multiple sclerosis, the regeneration of myelin sheaths often fails due to a default of the resident stem/precursor cells (oligodendrocyte precursor cells) to differentiate into mature myelin forming cells. Significant advances have been made in our understanding of the molecular and cellular processes involved in remyelination. Furthermore, important insight has been gained from studies investigating the interaction of stem/precursor cells with the distinct environment of demyelinating lesions. These suggest that successful regeneration depends on a signalling environment conducive to remyelination, which is provided in the context of acute inflammation. However, multiple sclerosis lesions also contain factors that inhibit the differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes. The pattern by which remyelination inducers and inhibitors are expressed in multiple sclerosis lesions may determine a window of opportunity during which oligodendrocyte precursor cells can successfully differentiate. As the first molecules aiming at promoting remyelination are about to enter clinical trials, this review critically evaluates recent advances in our understanding of the biology of oligodendrocyte precursor cells and of the stage-dependent molecular pathology of multiple sclerosis lesions relevant to the regeneration of myelin sheaths. We propose a model that may help to provide cues for how remyelination can be therapeutically enhanced in clinical disease.
Introduction
Myelin sheaths consist of highly organized lipid-rich membrane stacks surrounding axons, the conductive processes of neurons.
Recent data demonstrate that myelin sheaths also play an important role in maintaining and protecting axons (Irvine and Blakemore, 2008) . Although deletion of single myelin genes such as proteolipid protein (Griffiths et al., 1998) or 2 0 ,3 0 -cyclicnucleotide 3 0 -phosphodiesterase (CNP) (Lappe-Siefke et al., 2003) does not lead to overt structural changes of myelin sheaths, animals thus affected display enhanced chronic axonal degeneration. Therefore, myelin sheaths seem to also provide trophic support to myelinated axons. This view is further substantiated by the finding that myelin-associated glycoprotein knock-out mice, which are characterized by a similar phenotype and suffer from chronic axonal degeneration (Li et al., 1994) , display increased axonal loss when challenged by administration of gliotoxins (Nguyen et al., 2009) . Similarly, increased axonal loss has been observed following induction of experimental autoimmune encephalomyelitis , an autoimmune disease that resembles many of the features of multiple sclerosis (Nguyen et al., 2009) . One way to protect axons in the context of disease therefore is to ensure that myelin sheaths are maintained, or if lost that they are rapidly regenerated.
Remyelination in the adult central nervous system
Myelin regeneration in the adult CNS is mainly mediated by a multipotent parenchymal CNS stem/precursor cell population traditionally referred to as oligodendrocyte precursor cells. Following a demyelinating incident, oligodendrocyte precursor cells are rapidly amplified in areas of demyelination where they subsequently give rise to myelinating oligodendrocytes ( Fig. 1 , for a detailed review refer to Franklin, 2002; Franklin and ffrench-Constant, 2008) . Innumerable experiments have demonstrated that remyelination following experimental demyelination is a robust regenerative response and that drastic measures are required to induce failure. All the more surprising is that remyelination fails frequently in the context of multiple sclerosis. Post-mortem studies have revealed that remyelination failure in chronic multiple sclerosis lesions is in many cases associated with a presence of oligodendrocyte precursor cells that fail to differentiate into oligodendrocytes (Wolswijk, 1998; Chang et al., 2000; Kuhlmann et al., 2008) . While on some occasions disturbed recruitment of oligodendrocyte precursor cells may play a role, this review will summarize recent evidence from post-mortem and experimental studies that may provide answers to the questions why oligodendrocyte precursor cells fail to differentiate in multiple sclerosis lesions and which strategies may be able to promote oligodendrocyte precursor cell differentiation in a clinical setting.
Remyelination of multiple sclerosis lesions-data from human post-mortem and biopsy studies
Selective degeneration of myelin sheaths combined with relative preservation of axons has been recognized as the key hallmark of Adult OPC I. OPC recruitment II. OPC differentiation 1 2
Figure 1 CNS remyelination proceeds in distinct stages (Franklin, 2002) . The first stage consists in the recruitment of oligodendrocyte precursor cells (OPCs) into demyelinated areas, the second in the differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes. Oligodendrocyte precursor cell differentiation entails (1) making processes and contacting axons and (2) forming new myelin sheaths. Lesion associated oligodendrocyte precursor cell differentiation inhibitors (Table 1 ) may impact on one particular or both stages of oligodendrocyte precursor cell differentiation.
multiple sclerosis. This process, also termed 'primary demyelination', in most cases seems to be driven by a dysregulated immune system. However, more recently, further pathological mechanisms have also been implicated (Lassmann et al., 2001) . Although demyelination in multiple sclerosis has been extensively studied it remains unclear at which stage of the disease the main loss of oligodendrocytes occurs (Ozawa et al., 1994; Lucchinetti et al., 1999; Wolswijk, 2000) . Answering this question proves to be difficult as the tissue available for investigation commonly derives from very early stage multiple sclerosis lesions (biopsies) or late stages of lesion development (autopsies) (Ozawa et al., 1994; Lucchinetti et al., 1999) . Multiple sclerosis lesions are generally categorized according to the stage of the demyelinating activity and the presence of immune cells (Bruck et al., 1995; Frohman et al., 2006) . Active demyelinating lesions are defined by the presence of myelin-laden macrophages either throughout the lesion or at the lesion edge. In contrast, myelin-phagocytosing macrophages are rare and usually localized at the rim of so-called smouldering lesions. These are thought to be a correlate of the progressive phase of the disease (Prineas et al., 2001) . Finally, chronic inactive lesions do not harbour any evidence for ongoing demyelination although single T cells may be present in perivascular regions (Frohman et al., 2006) .
Apart from primary demyelination, a further important pathological feature of multiple sclerosis that has only recently been recognized to its full extent consists of the damage and loss of axons. Post mortem evidence suggests that axonal degeneration does not only take place in the context of early lesions but continues to occur during later stages of disease when acute inflammatory episodes are generally absent (Frischer et al., 2009; Androdias et al., 2010) . The cause for ongoing axonal degeneration in the absence of overt inflammation is elusive. One potential explanation is that the absence of myelin sheaths leads to a lack of axonal support that ultimately results in axonal degeneration (Li et al., 1994; Griffiths et al., 1998; Lappe-Siefke et al., 2003; Pohl et al., 2011) . On the other hand, persisting diffuse inflammation has also recently been linked to axonal loss (Androdias et al., 2010) . In this study the extent of diffuse axonal loss in the normal appearing white matter correlated with both the density of major histocompatibility complex class II + microglia in normal appearing white matter and the density of CD3 + T cells in the meninges.
Areas of remyelination in post-mortem brains affected by multiple sclerosis are often referred to as shadow plaques, reflecting the lighter staining pattern as compared with normal white matter using classic histological myelin stains. Although remyelination in response to primary demyelination is well documented and can be surprisingly efficient in a subset of individuals (Patrikios et al., 2006; Patani et al., 2007; Goldschmidt et al., 2009) , it often fails during the course of multiple sclerosis. As a result, fully remyelinated lesions are comparatively rare during late stages of the disease. However, in many lesions, remyelination does not fail entirely but instead remains restricted to a small rim of newly formed myelin sheaths at the lesion border (Patrikios et al., 2006) . Similar to other regenerative responses remyelination occurs most efficiently during early, active stages of multiple sclerosis lesion development that are characterized by the full plethora of inflammatory and lipid-laden cells and where oligodendrocyte precursor cells engaging in the formation of new myelin sheaths are frequently observed (Prineas et al., 1993) . In these active lesions the density of oligodendrocyte lineage cells is often comparable to the density found in the periplaque white matter (Ozawa et al., 1994; Bruck et al., 1995; Lucchinetti et al., 1999; Kuhlmann et al., 2008) .
In contrast, mature oligodendrocytes, as demonstrated by immunohistochemistry for NogoA or in situ hybridization for proteolipid protein messenger RNA are exceedingly rare in chronic multiple sclerosis lesions (Ozawa et al., 1994; Kuhlmann et al., 2008) . As chronic multiple sclerosis lesions often contain oligodendrocyte precursor cells that have become arrested at immature stages, a major reason for remyelination failure in multiple sclerosis is a block of oligodendrocyte precursor cell differentiation (Wolswijk, 2000 (Wolswijk, , 2002 Kuhlmann et al., 2008) . The reasons why oligodendrocyte precursor cells fail to differentiate are likely to be determined by intrinsic changes within the oligodendrocyte precursor cell population or the specific environment of multiple sclerosis lesions.
Multiple sclerosis lesion-associated determinants of CNS remyelination
In the past years two fundamental concepts in the biology of oligodendrocyte precursor cells have become apparent that can be summarized in a simplistic model. First, oligodendrocyte precursor cells rely on a driving force that stimulates their activation and recruitment, and potentially regulates their differentiation into oligodendrocytes. Many of the positive regulators required are provided in the context of acute inflammation that is associated with early stages of lesion formation (Hinks and Franklin, 1999; Arnett et al., 2001; Mason et al., 2001 Mason et al., , 2003 Kotter et al., 2005) but are absent in a more chronic inflammatory environment (Foote and Blakemore, 2005; Franklin and ffrenchConstant, 2008) . Second, the process of oligodendrocyte precursor cell differentiation is susceptible to negative cues that form part of the environment of non-remyelinating multiple sclerosis lesions.
As an increasing number of negative regulators of oligodendrocyte precursor cells are being identified in multiple sclerosis lesions, the question emerges whether these factors all contribute to the same extent, or whether factors can be identified that in the context of the clinical and pathological course of multiple sclerosis are more likely to determine the failure of remyelination than others. In this respect, the temporal pattern at which individual factors emerge in multiple sclerosis lesions may be of fundamental importance.
Factors that promote oligodendrocyte precursor cell differentiation
Similar to other stem/precursor cells oligodendrocyte precursor cells are highly responsive to environmental stimuli. In tissue culture oligodendrocyte precursor cells can be maintained at an undifferentiated, proliferative stage in the presence of growth factors such as PDGFaa and fibroblast growth factor-2. Differentiation is often initiated by changing the medium to a more complex multifactorial cocktail (McCarthy and de Vellis, 1980; Colognato et al., 2004; Baer et al., 2009) . A number of single factors are able to promote oligodendrocyte precursor cell differentiation in vitro when added to serum-containing differentiation medium. These range from factors that form part of the extracellular matrix such as b1 or b5 integrin (Buttery and ffrench-Constant, 1999; Blaschuk et al., 2000; Relvas et al., 2001 ) and vitronectin (Sobel et al., 1995; Gutowski et al., 1999) to neurotransmitters that act at glutamate receptors and at b-adrenoreceptors (Steinhauser and Gallo, 1996; Ghiani et al., 1999) , to secreted factors that are expressed in demyelinating lesions. For example, it was recently demonstrated that the chemokine CXCL12, which also is expressed in active multiple sclerosis lesions, is able to accelerate oligodendrocyte precursor cell differentiation via its receptor CXCR7 in the context of serum-containing differentiation medium (Gottle et al., 2010) .
The finding that a combination of factors are required to stimulate oligodendrocyte precursor cell differentiation also translates into in vivo models of remyelination, although the factors may differ as there are high levels of redundancy. Numerous positive stimuli for the process of remyelination have been identified, including various growth factors and chemokines. But although these factors contribute to a pro-remyelination environment they are often unable to promote remyelination on their own (O'Leary et al., 2002; Woodruff et al., 2004) .
The multifactorial environment required for successful remyelination seems to be provided in the context of an acute inflammatory response as experimental depletion of macrophages (Kotter et al., 2001) , B or T cells impacts negatively on the process of remyelination. Furthermore, studies have demonstrated that dampening of the acute immune response by administration of a course of steroids modelled according to clinical steroid regiments results in a delay in CNS remyelination (Chari et al., 2006) . As to be expected, steroid treatment resulted in a reduction in the number of macrophages and an impairment of their phagocytic activity (Chari et al., 2006) . As steroid administration did not alter the colonization of the lesions by oligodendrocyte precursor cells it was concluded that the delay in remyelination was caused by a delay in oligodendrocyte precursor cell differentiation.
Similarly, the dampened inflammatory environment in chronic silent lesions seems to lack the driving factors required for successful remyelination (Wolswijk, 2002; Foote and Blakemore, 2005) to stimulate CNS remyelination. In chronic MS lesions oligodendrocyte precursor cells may be present in sufficient numbers they fail to become activated and engage in the process of remyelination.
Based on the differences between efficient myelin regeneration in acute and inefficient chronic multiple sclerosis lesions (Prineas and Connel, 1979; Raine and Wu, 1993 ) the concept of 'time' emerges as being fundamentally important for the success of remyelination in multiple sclerosis (Miller and Mi, 2007; Franklin and ffrench-Constant, 2008) .
The most obvious temporal changes occurring over time in multiple sclerosis lesions are changes in the inflammatory response. As time progresses, the remyelination-promoting effects of acute inflammation give way to a chronic inflammatory milieu. On the basis of these findings, a model can be formulated, which suggests that in multiple sclerosis a window of opportunity exists during which oligodendrocyte precursor cell differentiation can successfully occur. This window of opportunity opens up following sufficient expansion of oligodendrocyte precursor cells and ends with the conversion of the acute to chronic inflammation ( Fig. 2A) .
Inhibitors of oligodendrocyte precursor cell differentiation present in chronic multiple sclerosis lesions A number of studies have identified specific oligodendrocyte precursor cell differentiation inhibitors in multiple sclerosis lesions that are able to negatively impact on the transient environment conducive to remyelination and thus must also be considered in the proposed model. The composition of oligodendrocyte precursor cell differentiation inhibiting factors in multiple sclerosis lesions changes significantly over time. On the basis of post-mortem evidence of brains affected by multiple sclerosis, lesion-associated inhibitors can be grouped into early and late stage inhibitors (Table 1) . Whereas early stage inhibitors appear during phases of ongoing inflammation and may persist for extended periods, expression of late stage inhibitors is restricted to chronic non-inflammatory multiple sclerosis lesions.
Polysialylated-neural cell adhesion molecule
The first lesion-associated inhibitors of oligodendrocyte precursor cell differentiation that have been identified are predominantly expressed in chronic multiple sclerosis lesions. These include polysialylated-neural cell adhesion molecule (PSA-NCAM), which is also the only known example of a negative regulator of myelin sheath formation produced by axons. A correlation between down-regulation of PSA-NCAM and the onset of myelination in vitro in the context of development suggested that PSA-NCAM may act as an inhibitor of myelin sheath formation (Charles et al., 2000) . More recent studies have found that PSA-NCAM is expressed on demyelinated axons in chronic inactive multiple sclerosis lesions (Charles et al., 2002) . In contrast, Enhancing remyelination in disease axons in acute lesions characterized by inflammatory infiltrates and lesions that underwent remyelination did not show evidence of PSA-NCAM expression. Functional data that PSA-NCAM can negatively regulate myelin formation derive from studies demonstrating that antibody-mediated masking or removal of PSA sites by treatment with endoneuraminidase N, an enzyme that specifically hydrolyses PSA, can promote the formation of myelinating internodes in mouse neuron-oligodendrocyte co-cultures (Charles et al., 2000) . Furthermore, it was recently demonstrated that remyelination after cuprizone-induced demyelination is accelerated in mice deficient in the PSA synthesizing enzyme St8SiaIV (Koutsoudaki et al., 2010) .
Hyaluronan
Another factor that has been implicated in the inhibition of oligodendrocyte precursor cell differentiation in chronic multiple sclerosis lesions involves the accumulation of high molecular weight hyaluronan. Hyaluronan is a glycosaminoglycan produced by reactive astrocytes (Back et al., 2005) . Rat oligosphere-derived oligodendrocyte precursor cells grown in the presence of high molecular weight hyaluronan show a reversible reduction in process complexity as well as a significant impairment in the expression of myelin basic protein, a structural component of myelin sheaths frequently used as a marker for mature oligodendrocytes. Furthermore, in astrocyte-oligodendrocyte co-cultures, treatment with hyaluronidase induces an increase in the number of myelin basic protein-positive cells supporting the notion that astrocyte-derived high molecular weight hyaluronan is able to inhibit the differentiation of oligodendrocyte precursor cells (Back et al., 2005) . However, whether the increase in myelin basic protein expression predicts the ability of the cells to myelinate axons in vivo remains to be established. A clinical relevance of hyaluronan is proposed by expression of hyaluronan in chronic demyelinated lesions that coincides with elevation of CD44 expression in astrocytes. In contrast, reduced levels of hyaluronan are found in areas of remyelination.
Taken together, PSA-NCAM and high molecular weight hyaluronan expression in multiple sclerosis lesions may act synergistically at shortening the window of opportunity during which remyelination can successfully occur ( Fig. 1-I ). On the other hand, inhibitors present at acute and subacute stages following demyelination are able to delay the onset of oligodendrocyte precursor cell differentiation and thus defer the onset of remyelination in multiple sclerosis ( Fig. 1-II) .
Inhibitors of oligodendrocyte precursor cell differentiation present in acute and subacute multiple sclerosis lesions
Notch1-signalling
The first evidence of a potential inhibitor expressed at early stages following demyelination was the identification of partners of the canonical Notch-signalling pathway in multiple sclerosis lesions (John et al., 2002) . Notch-jagged1 signalling was previously known as a negative developmental regulator of oligodendrocyte precursor cell differentiation during development (Wang et al., 1998) . Jagged1 is expressed by cultured astrocytes in response to TGF-b and by hypertrophic astrocytes located on the lesion border of acute and chronic active multiple sclerosis lesions (John et al., 2002) . Notch-1 positive oligodendrocyte lineage cells were identified in proximity to jagged-1-expressing astrocytes. A regulatory role of Notch-jagged signalling on primary human oligodendrocyte marker-4 + CNPase + myelin basic proteinoligodendrocytes was demonstrated by culturing the cells on 2T2 cell monolayers stably transfected with full-length human jagged1 (John et al., 2002) . While oligodendrocyte precursor cells reached a myelin basic protein-positive stage irrespective of the presence of jagged1, process formation in the presence of jagged1 was significantly compromised. However, it remains unclear whether in vitro changes in process formation in the absence of transcriptional changes in oligodendrocyte precursor cells can be considered as a correlate for a failure of oligodendrocyte precursor cell differentiation in vivo. Further uncertainty derives from a subsequent in vivo study, which demonstrated that conditional ablation of Notch-1 in Plp-creER Notch1 lox/lox transgenic mice does not affect remyelination following toxin-induced demyelination although an abundance of jagged1 expression is generally present in experimentally demyelinated lesions (Stidworthy et al., 2004) . Jagged1 and Notch-1 expression were also reported in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis, a T cell-mediated model of chronic multiple sclerosis (Mix et al., 2010) . In this model Notch1-positive oligodendrocytes were exclusively detected in remyelinating lesions and absent in lesions without signs of remyelination (Seifert et al., 2007) . Paradoxically, in a similar model, inhibition of Notch signalling by gamma-secretase, an enzyme known to hydrolyse the membrane-spanning domain of Notch, was able to promote functional recovery (Jurynczyk et al., 2005) . However, as T cells and dendritic cells are also known to express Notch1, improved recovery may also be related to immunomodulatory effects of gamma-secretase (Jurynczyk and Selmaj, 2010) . The most convincing evidence of an inhibitory role of Notch1 for the process of remyelination was reported by a study in which targeted Notch1 inactivation in oligodendrocyte precursor cells was achieved using Olig1Cre:Notch1 12f/12f mice (Zhang et al., 2009) . The differentiation of Olig1Cre:Notch1 12f/12f mice derived oligodendrocyte 
Wnt signalling
A further pathway that has been implicated in the regulation of oligodendrocyte precursor cell differentiation in multiple sclerosis is Wnt signalling . The Wnt pathway is involved in many developmental processes and has also been implicated in myelination. Conditional activation of b-catenin in oligodendrocyte lineage cells causes a delay of remyelination due to a delay in oligodendrocyte precursor cell differentiation in vivo (Chien et al., 2009; Inestrosa and Arenas, 2010) and their expression in and relevance to multiple sclerosis lesions remains to be determined.
Semaphorin 3A as inhibitor of oligodendrocyte precursor cell differentiation Semaphorin 3A (Sema3A), a member of the secreted class 3 semaphorins, is a further molecule expressed at acute to subacute stages in multiple sclerosis lesions (Williams et al., 2007) that has the potential to negatively impact on CNS remyelination. Because Sema3A exerts repulsive effects on migration of oligodendrocyte precursor cells it was proposed that Sema3A expression may prevent repopulation of demyelinated lesions with oligodendrocyte precursor cells (Spassky et al., 2002) . However, despite expression of Sema3A in experimental as well as in multiple sclerosis lesions (Williams et al., 2007; Syed et al., 2010 ) the recruitment of oligodendrocyte precursor cells is not generally deficient (Wolswijk, 1998 (Wolswijk, , 2000 Chang et al., 2000 Chang et al., , 2002 Kuhlmann et al., 2008) . A potential explanation for this discrepancy is provided by expression of semaphorin 3F (Sema3F), another member of class 3 semaphorins in demyelinated lesions (Williams et al., 2007) , which acts as a chemo-attractant and mitogenic factor for oligodendrocyte precursor cells (Spassky et al., 2002) . Experimental evidence suggests that Sema3A is able to induce a reversible reduction of process complexity in cultured adult oligodendrocyte lineage cells (Ricard et al., 2001 ) and cause redirection of oligodendrocyte lineage cell growth cones away from Sema3A (Cohen et al., 2003) . More recently, Sema3A emerged as a potent inhibitor of oligodendrocyte precursor cell differentiation following a screen that assessed the effects of a number of molecules expressed in the injured CNS (Syed et al., 2008 (Syed et al., , 2010 . Assessment of oligodendrocyte marker-4 reactivity and myelin basic protein messenger RNA expression demonstrated that addition of Sema3A to cultured rat oligodendrocyte precursor cells induces a potent and reversible inhibition of oligodendrocyte precursor cell differentiation. The inhibition was maintained for as long as Sema3A was present in the medium. However, when Sema3A was removed the cells were able to differentiate. In agreement with the studies of Sema3A on adult oligodendrocyte lineage cells (Cohen et al., 2003) , oligodendrocyte precursor cells reacted to the presence of Sema3A not only during the early stages of differentiation but remained responsive 2 days after the initiation of the differentiation process. To assess effects of Sema3A on remyelination in vivo, gliotoxic lesions were induced in the caudal cerebellar peduncle and recombinant human Sema3A-Fc administered stereotactically. Although the overall presence of oligodendrocyte precursor cells was not affected in Sema3A treated lesions, the vast majority of axons remained demyelinated. Furthermore, processes of cells reminiscent of oligodendrocyte precursor cells contacted many of the axons but failed to form compact myelin sheaths. These findings bear resemblance with oligodendrocyte precursor cells contacting axons but failing to differentiate in multiple sclerosis lesions (Wolswijk, 1998) . Although our in vitro findings seem to translate directly into the situation in vivo, it is possible that Sema3A exerts additional indirect effects via regulation of other cell types present in multiple sclerosis lesions (Pasterkamp et al., 1998; De Winter et al., 2002; Spassky et al., 2002; Zhou et al., 2008; Ji et al., 2009) .
In multiple sclerosis, Sema3A and Sema3F expression is restricted to active plaques and is not found in chronic lesions or normal white matter (Williams et al., 2007) . Whereas increased levels of Sema3F expression can be detected in acute inflammatory lesions, the highest levels are associated with later lesion stages characterized by a lesser degree of inflammation. These findings suggest that while attractive cues may dominate early stages of lesion development, they give way to aversive cues as the disease progresses. Conversely, if the recruitment or differentiation of oligodendrocyte precursor cells at early stages is insufficient, an imbalance favouring Sema3A expression may have the potential to interfere with both oligodendrocyte precursor cell recruitment and differentiation and thus contribute to remyelination failure in multiple sclerosis.
Myelin associated inhibitors of CNS remyelination
More recently, a role for inhibitors of oligodendrocyte precursor cell differentiation that appear at the earliest stage and as a direct consequence of demyelination has become apparent. These form part of myelin debris that accumulates as a result of the disintegration of myelin sheaths. The presence of myelin debris is easily demonstrated following toxin-mediated demyelination (Shields et al., 1999; Woodruff and Franklin, 1999) . Thus, an important function of macrophages, which initially appear at the border of demyelinated lesions ( Fig. 2A and B) , is the phagocytosis of myelin-associated inhibitors (Kotter et al., 2005 . Remyelination in experimental lesions follows a similar pattern: new myelin sheaths first appear at the lesion border behind the line of macrophages in areas where myelin debris has been cleared ( Fig. 2A and B) . Similarly, in multiple sclerosis, remyelination is also most often seen at the lesion border where macrophages are most abundant during later stages of the disease (Patrikios et al., 2006) . The hypothesis that myelin debris can act as a rate-determining factor in the process of remyelination was verified by an experiment in which the endogenous myelin load in demyelinated lesions was supplemented with extrinsic myelin preparations . This resulted in a reduction in the number of activated oligodendrocyte precursor cells expressing the transcription factor Nkx2.2 that has been implicated in early stages of oligodendrocyte precursor cell differentiation (Fancy et al., 2004) and a nearby complete block of remyelination. However, the overall presence of undifferentiated platelet derived growth factor receptor (PDGFR-) positive oligodendrocyte precursor cells remained unaffected. Ultrastructural analysis of myelinsupplemented lesions showed that axons remained denuded (Fig. 3C) although some of the axons were contacted by cellular processes resembling those of oligodendrocyte precursor cells. The lack of multiple sclerosis tissue available for electron microscopy has until recently hampered a systematic assessment of the question whether myelin breakdown products accumulate in multiple sclerosis lesions. Nevertheless, single specimens that have become available suggest that myelin-debris is indeed present in active multiple sclerosis lesions (Fig. 2D) .
Myelin associated inhibitors inhibit the progression of oligodendrocyte precursor cells along the lineage and lead to an oligodendrocyte marker-4 immunonegative stage in vitro (Robinson and Miller, 1999) . Antibodies against oligodendrocyte marker-4 identify late oligodendrocyte precursor cells by reacting with the sulphated glycolipid antigen pro-oligodendrocyte antigen and differentiate oligodendrocyte lineage cells by reacting with sulphated galactosylcerebroside (Bansal et al., 1989) . Furthermore, expression of myelin basic protein as well as the formation of complex processes is strongly impaired in the presence of myelin-associated inhibitors (Baer et al., 2009) . As myelin is a highly specialized membrane unusually rich in lipids, the question was raised whether the inhibitory activity lies within the lipid or the protein compartment. Experiments in which myelin extracts were treated with proteinase or lipase demonstrated that the inhibitory activity is associated with myelin protein (Syed et al., 2008) . Although we found that similar intracellular cascades to those involved in the inhibition of axon growth by myelin-associated inhibitors mediate inhibitory effects on oligodendrocyte precursor cells, including RhoA and PKC signalling (Baer et al., 2009) . Intriguingly, none of the major myelin-associated axon growth inhibitors including NogoA, myelin-associated glycoprotein and oligodendrocyte myelin exert negative effects on oligodendrocyte precursor cell differentiation (Syed et al., 2008) . The fact that myelin of the peripheral nervous system does not exert inhibitory effects on oligodendrocyte precursor cell differentiation may provide helpful clues in search of the molecular substrate in CNS myelin responsible for mediating inhibitory effects on OPC differentiation (Syed et al., 2008) . However, this has not yet been identified.
Misguided differentiation of oligodendrocyte precursor cells as a cause of remyelination failure in multiple sclerosis
Most attempts at explaining why oligodendrocyte precursor cells fail to give rise to mature oligodendrocytes in multiple sclerosis lesions do not take into consideration that oligodendrocyte precursor cells are multipotent progenitor cells capable of generating cells of various lineages. The ability of oligodendrocyte precursor cells to form oligodendrocytes and type 2 astrocytes (2A) in vitro has been recognized since their initial description. For this reason, oligodendrocyte precursor cells were traditionally referred to as O-2A-progenitors. However, over extended periods it was debated whether the formation of astrocytes by oligodendrocyte precursor cells is a tissue artefact or whether astrogliogenesis from oligodendrocyte precursor cells actually takes place in vivo. Studies transplanting the oligodendrocyte precursor cell line CG4 into glial-depleted regions of the CNS suggested bipotential capacity in vivo as transplanted cells contributed to reconstitution of both astrocytes and myelinating oligodendrocytes (Franklin et al., 1995) . Furthermore, a recent series of lineage-tracing studies confirmed that oligodendrocyte precursor cells may in principle be able to contribute to the generation of astrocytes during development and tissue homeostasis in vivo. The use of Ng2creBAC mice crossed with a Cre reporter Z/EG strain demonstrated that although the progeny of oligodendrocyte precursor cells mainly consist of myelinating oligodendrocytes, Ng2-positive cells also formed a subpopulation of protoplasmic astrocytes in the grey matter of the ventrolateral forebrain and the spinal cord (Zhu et al., 2008a, b) . In contrast, studies based on Pdgfra-creERT2/ Rosa26-YFP double-transgenic mice indicated that oligodendrocyte precursor cells routinely engender oligodendrocytes and, surprisingly, projection neurons primarily located in the piriform cortex, but not astrocytes (Rivers et al., 2008) . Potential explanations for these contradictory results include the presence of specific oligodendrocyte precursor cell subpopulations that are characterized by differences in Ng2 and Pdgfr-expression, regional differences or ectopic expression of Ng2 in cells other than oligodendrocyte precursor cells.
Based on the ability of oligodendrocyte precursor cells to form astroglia, a further potential explanation for remyelination failure in multiple sclerosis lies in a misguided differentiation of oligodendrocyte precursor cells into astrocytes. Theoretically, this would lead to the typical phenotype of chronically demyelinated lesions consisting of bundles of denuded axons surrounded by a dense astroglial matrix.
Molecular regulators of lineage choice in oligodendrocyte precursor cells
An astroglial fate of oligodendrocyte precursor cells in culture can be induced efficiently by medium containing high levels of foetal calf serum while culture in serum concentrations between 1 and 10% results in mixed clones made of oligodendrocytes and astrocytes (Lubetzki et al., 1992) . A number of specific molecules have been found to induce astrocyte formation including signalling factors and factors of the extracellular matrix. Whereas the presence of ciliary neurotrophic factor transiently stimulates glial fibrillary acidic protein (Gfap) expression in oligodendrocyte precursor cells without ultimately influencing lineage commitment (Hughes et al., 1988; Lillien et al., 1990) addition of ciliary neurotrophic factor in combination with the presence of extracellular matrix molecules of meningeal or endothelial cells results in stable induction of astroglial fate (Lillien et al., 1990) . Interestingly, the same study also demonstrated that extracellular matrix-associated molecules alone are able to inhibit oligodendrocyte differentiation in the absence of ciliary neurotrophic factor, indicating another potential source of lesion-associated differentiation inhibitors in multiple sclerosis that demands further attention.
Similar to ciliary neurotrophic factor, leukaemia inhibitory factor and oncostatin M signal via gp130/leukaemia inhibitory factor receptor b to exert comparable effects on oligodendrocyte precursor cells (Gard et al., 1995) . However, the ciliary neurotrophic factor/extracellular matrix-associated astrocyte-inductive activity is restricted to early oligodendrocyte precursor cell stages before the onset of oligodendrocyte marker-4 immunoreactivity, whereas astrocyte-inducing effects of high levels of foetal calf serum continue throughout the oligodendrocyte marker-4 stage (Gard et al., 1995) .
Foetal calf serum is known to contain high levels of bone morphogenic proteins (BMPs) and indeed, a number of studies have indicated that BMP2, 4 and 7 are able to induce astroglial differentiation of cultured oligodendrocyte precursor cells while at the same time inhibiting the generation of oligodendrocytes (Mabie et al., 1997) . BMP-mediated astroglial induction is dosedependent and is accompanied by increased cellular survival and accelerated exit from cell cycle. Furthermore, transient exposure of oligodendrocyte precursor cells to BMPs is sufficient to induce astrocytic fate and reduce oligodendrocyte differentiation whereas extended exposure of BMP causes an increase in the number of cells induced to turn into astrocytes (Mabie et al., 1997) . These findings suggest that a molecular switch exists controlling astrocyte differentiation, which can be activated with a brief stimulus of BMPs. Studies in which oligodendrocyte precursor cells cultured under oligodendrocyte-inducing conditions were exposed to BMP at delayed time points indicate a gradual but progressive loss of the responsiveness to BMP coinciding with exit from the cell cycle and terminal oligodendrocyte differentiation (Mabie et al., 1997) . The astrocyte-inducing and oligodendrogenesis-inhibiting effects of BMPs were subsequently confirmed in vivo by over-expression of BMP4 under control of the neuron-specific enolase promoter (Gomes et al., 2003) . Paradoxically, BMP signalling also seems to be essential for the formation of fully differentiated myelinating oligodendrocytes (See et al., 2007) .
Effects of BMPs are counteracted by a number of natural antagonists, one of which is Noggin (Sabo et al., 2009) . Depletion of Noggin by RNA interference-mediated gene silencing under low, non-2A inducing concentration of foetal calf serum in culture inhibits oligodendrocyte precursor cells proliferation and induces type 2 astrocyte formation (Kondo and Raff, 2004) . In contrast, enforced expression of Noggin blocks foetal calf serum-induced 2A differentiation. Because in the developing rat optic nerve the presence of BMP has been shown to coincide with expression of Noggin, a balance of astrocyte-inducing and astrocyte induction inhibiting factors may control oligodendrocyte precursor cells fate during development.
A series of elegant studies have investigated the mechanisms by which BMPs regulate astroglial fate determination in oligodendrocyte precursor cells and related neural progenitors. BMPs and leukaemia inhibitory factor act synergistically to promote astrocyte differentiation by inducing complex formation of the transcription factors Smad1 and Stat3 with p300 in the nucleus, resulting in direct activation of the Gfap promoter (Nakashima et al., 1999) . In contrast, by interacting with p300, Olig2 abolishes the complex formation between smad1, Stat3 and p300 and thus represses induction of astrocyte-specific Gfap (Fukuda et al., 2004) .
Microarray-based genomic comparison of neurosphere-derived mouse oligodendrocyte precursor cells cultured in the presence and absence of BMP4 pointed to inhibitor of DNA binding (Id1-4) genes as further downstream effectors of BMP (Samanta and Kessler, 2004) . Lentivirus-mediated transfection of cells functionally confirmed the ability of Id2 and especially Id4 to induce astroglial fate and inhibit oligodendroglial induction. Conversely, RNA interference-mediated gene silencing demonstrated that Id2 and Id4 act as downstream effectors of Bmp4. Inhibitor of DNA binding proteins do not comprise basic DNA binding domains. In order to act as dominant negative transcriptional regulators inhibitor of DNA binding proteins therefore bind to basic helix-loop-helix transcription factors. Co-immunoprecipitations with overexpressed inhibitor of DNA binding and my-his5-tagged OLIG proteins demonstrated that OLIG1 and OLIG2 form complexes with ID2 and ID4. Evidence that ID2 and ID4 interact directly with OLIG1/2 derive from bacterial two-hybrid assays expressing the Olig genes in bait vectors and the Id genes in target vectors. However, further indirect mechanisms may exist as inhibitor of DNA binding proteins also bind to E2A proteins expressed by oligodendrocyte precursor cells (Sussman et al., 2002) , which are also known to interact with OLIG proteins. Early studies identifying cells that label with both oligodendrocyte marker-4 and Gfap following virus-mediated demyelination propose that the specific environment in disease may cause astroglial induction in oligodendrocyte precursor cells (Godfraind et al., 1989) . However, as transient Gfap expression is found in oligodendrocyte precursor cells differentiating along the oligodendrocyte lineage as well as in Schwann cells, this evidence must be carefully evaluated. A number of experimental studies, however lacking the rigour of fate-mapping techniques, also propose that oligodendrocyte precursor cells may give rise to astrocytes following injury. For example, the cellular dynamic and antigenic profile of BrdU labelled dividing cells suggested that a proportion of oligodendrocyte precursor cells may become committed to astrocytes following cortical stab injury (Magnus et al., 2007) . Moreover, treatment with thyroid hormone after cortical cryo-injury resulted in an increase of oligodendrocytes with a concomitant decrease in astrocytes (Tatsumi et al., 2005) , whereas Noggin-FbAb-mediated neutralization of BMPs resulted in an increase in the number of Ng2-positive/Gfap-positive cells with type 2 astrocyte-like features following cortical injury (Hampton et al., 2007) .
Following induction of myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis, cells were identified that stained positively for Gfap, Nkx2.2 and Olig2 and thus were suggestive of intermediate stages of oligodendrocyte precursor cells commitment to the astrocyte lineage (CassianiIngoni et al., 2006) . As cytoplasmatic translocation of Olig2 has been implicated in the inactivation of Olig2 (Setoguchi and Kondo, 2004) , which is essential for astrocyte differentiation (Gabay et al., 2003; Fukuda et al., 2004) , evidence of cytoplasmatic expression of Olig2 in Gfap + cells of animals affected by experimental autoimmune encephalomyelitis seemed to strengthen this view. Furthermore, the detection of Ng2 + cells and Nkx2.2 + cells with both nuclear and cytoplasmic Olig2 suggested an ongoing commitment of oligodendrocyte precursor cells to an astrocytic fate. However, only a minor proportion (515%) of Gfap + cells in the lesion expressed Nkx2.2 while the majority of cells with nuclear and cytoplasmic Olig2 co-expressed Gfap and were negative for Ng2. Finally, the exposure of primary cells sorted on the basis of Ng2 and A2B5 expression to IFN-, a molecule that has been functionally implicated in the pathogenesis of multiple sclerosis (Panitch et al., 1987; Horwitz et al., 1997; Mycko et al., 2004) , results in down-regulation of Ng2, translocation of Olig2 from the nucleus to the cytoplasm and expression of Gfap, all potentially indicative of astroglial fate commitment of OPCs. However, because Olig2 was recently also identified as a critical factor for reactive astrocyte proliferation following cortical injury (Chen et al., 2008) Olig2 expression in the majority of Gfap + cells may actually be indicative of astrocyte-derived astrocytes. This interpretation is consistent with studies examining the fate of oligodendrocyte precursor cells following toxin-mediated demyelination in Pdgfr-creERT2: Rosa26-YFP mice, which found that at most, a small proportion of astrocytes were formed by oligodendrocyte precursor cells (Zawadzka et al., 2010) . The use of Fgfr3-creERT2: Rosa26-YFP mice, in which astrocytes and putative stem/progenitor cells around the central canal within the spinal cord are specifically labelled (Young et al., 2010) , further confirmed that in toxin-induced lesions the majority of astrocytes derive from proliferating astroglia in the vicinity. However, toxin-induced and auto-inflammatory demyelinating lesions may differ with respect to expression of astrocyte-inductive factors such as IFN- (Mycko et al., 2004; Kantarci et al., 2008) or BMPs (Ara et al., 2008) and thus the experimental findings summarized do not categorically preclude the formation of astrocytes by oligodendrocyte precursor cells in multiple sclerosis. Experimental evidence that signalling factors expressed in injured lesions are able to determine astroglial fate choice in oligodendrocyte precursor cells derives from transplantation of embryonic neurosphere-derived A2B5/NG2-positive cells into areas of spinal cord contusion injury (Lu et al., 2010) . These results in the generation of only a few oligodendrocytes while most transplanted cells adopt an astrocytic fate. Furthermore, culture of A2B5/Ng2-positive precursors in the presence of spinal cord homogenates strongly induces astrocyte differentiation whereas addition of the BMP inhibitor Noggin partially reverses the astrocyte differentiation inducing activity.
Lineage-tracing studies of PDGFR-positive cells in toxinmediated demyelinating lesions established that the majority of Schwann cells in the lesions derive from oligodendrocyte precursor cells (Zawadzka et al., 2010) . Interestingly, specification of oligodendrocyte precursor cells into Schwann cells may also be dependent on BMP as engraftment of Noggin over-expressing adult oligodendrocyte precursor cells into irradiated demyelinated lesions is sufficient to suppress Schwann cell-like differentiation (Talbott et al., 2006) . The ability of A2B5/Ng2-positive precursors to form astrocytes and Schwann cells may potentially be determined by their developmental stage as transplantation of embryo-derived A2B5/Ng2-positive cell populations into glial free CNS environments resulted in the formation of astrocytes; whereas transplanted adult oligodendrocyte precursor cells give rise to oligodendrocytes and Schwann cells (Talbott et al., 2006) .
In conclusion, the ability to form multiple cell types demonstrates the oligodendrocyte precursor cell's multipotent capacity, which is similar to that of a stem cell (Belachew et al., 2003; Rivers et al., 2008; Zhu et al., 2008; Zawadzka et al., 2010) . While the concept of a misguided differentiation of oligodendrocyte precursor cells into astrocytes in theory offers a compelling explanation for the evolvement of astroglia-dense chronic demyelinated multiple sclerosis plaques, evidence that this process may play a role in disease is limited and further stringent post-mortem and experimental studies are needed.
Further roles of bone morphogenic protein signalling in multiple sclerosis lesions
Another possibility by which BMPs may be able to compromise remyelination and promote glial scarring is by exerting direct effects on astrocytes (Fuller et al., 2007) . For example, BMP4 and 7 induce Sma1 translocation into the nucleus and an increase in the phosphorylation of Smad1, 5 and 8 in cultured mature astrocytes. This results in increased expression of Gfap and chondroitin sulphate proteoglycans. Chondroitin sulphate proteoglycans may also be factors that contribute to the remyelination aversive environment in multiple sclerosis lesions as the presence of chondroitin sulphate proteoglycans negatively affects the formation of membranous processes in primary mouse oligodendrocyte precursor cells (Kippert et al., 2009) .
Evidence of BMP signalling activity in multiple sclerosis lesions derives from studies demonstrating increased expression of the SMAD transcriptional co-repressors SKI and SNO in margins of active lesions as compared with chronic lesions (Mycko et al., 2004) . Furthermore, multiple sclerosis lesions are characterized by increased levels of GFAP and SMAD6 expression (Lock et al., 2002) . Thus BMP signalling activity in multiple sclerosis lesions may prompt astrocytes to contribute to the remyelination-aversive environment of multiple sclerosis lesions independent of regulating oligodendrocyte precursor cells fate choices.
Failure of remyelination in disease
A critical factor determining the efficiency of remyelination is age. The age-dependent decrease in the efficiency of remyelination is associated with a delay in both the recruitment of macrophages and in the clearance of myelin debris (Hinks and Franklin, 1999; Shields et al., 1999) . Therefore, a prolonged presence of myelinassociated inhibitors may impact on the efficiency of remyelination in aged animals. More recent studies have demonstrated an age-related reduction in the reactivity of oligodendrocyte precursor cells, which is associated with a delayed recruitment of histone deacetylases (Hdacs) to promoter regions of differentiation inhibitors (Marin-Husstege et al., 2002; Shen et al., 2005) . However, the age-related decrease in cellular activity does not preclude successful remyelination and oligodendrocyte precursor cells in aged animals remain intrinsically capable of remyelinating axons (Shields et al., 1999; Sim et al., 2002; Penderis et al., 2003) .
A further possibility, which may account for remyelination failure in multiple sclerosis and needs to be explored in more detail is that oligodendrocyte precursor cells may become pathogenic and lose the ability to respond to differentiation-inducing signals. This possibility has been implicated by a recent study demonstrating the presence of non-canonical NOTCH1 ligands in chronic multiple sclerosis lesions (Nakahara et al., 2009) . Non-canonical NOTCH1 ligands such as FC3/Contactin expressed on axons transduce signal through NICD/Deltex, evoke transcriptional activation of myelin genes such as myelin-associated glycoprotein and are able to promote oligodendrocyte precursor cell differentiation and myelination (Popko, 2003; D'Souza et al., 2008) . However, in inactive chronic multiple sclerosis lesions, CONTACTIN may fail to induce oligodendrocyte precursor cell differentiation as a consequence of pathologic TIP30 expression in oligodendrocyte precursor cells (Nakahara et al., 2009 ).
TIP30 is a cellular protein that had originally been identified as a tumour suppressor due to its apoptosis-inducing effects. Over-expression of TIP30 in OLN-39 cells, a cell line resembling oligodendrocyte precursor cells and immature oligodendrocytes with respect to morphology and antigenic properties, resulted in a block of Contactin-induced differentiation. While the authors found that cytoplasmatic NICD/TIP30 was reduced in areas of remyelination higher levels of NICD/TIP30 were detected in chronically demyelinated MS plaques. Thus, it is conceivable that the intrinsic ability of oligodendrocyte precursor cells to differentiate is lost during chronic stages of demyelination.
On the basis of the window of opportunity model, four scenarios can be envisaged that negatively impact on remyelination in MS and result in a failure of remyelination as a consequence of failed oligodendrocyte precursor cell differentiation (Fig. 2B) . These are characterized by: (i) an untimely transition of the acute inflammatory to a chronic inflammatory environment (Fig. 2B-I) ; (ii) a prolonged presence of early inhibitors (Fig. 2B-II) ; (iii) a premature expression of late inhibitors of oligodendrocyte precursor cell differentiation, or by combinations of the above (Fig. 2B-III) . Furthermore, (Fig. 2C ) and (iv) although more speculative, expression of factors that induce astroglial fate of oligodendrocyte precursor cells may contribute to remyelination failure in MS (Fig. 2C) .
The occurrence of such drastic events in multiple sclerosis is supported by the frequent presence of partially remyelinated multiple sclerosis plaques. Although radical changes of the immune system have long been recognized in the course of multiple sclerosis, hardly anything is known about how they impact on the process of remyelination. This lack of knowledge provides the ground for interesting future studies.
Changes in the inflammatory environment may also influence the presence of lesion-associated inhibitors. For example, the phagocytic activity of macrophages is regulated by inflammatory factors (Bruck et al., 1992; Lazarov-Spiegler et al., 1998; Neumann et al., 2009) and thus the clearance of myelinassociated inhibitors may be affected by alterations of the immune response. In contrast, it remains unclear whether premature expression of late stage inhibitors such as PSA-NCAM or high molecular weight hyaluronan can actually occur and thus impact on the window of opportunity.
Consequences for strategies aiming at promoting CNS remyelination
The window of opportunity model predicts that strategies aiming at promoting CNS remyelination in multiple sclerosis must take into account the stage of the disease. In acute/subacute multiple sclerosis lesions the immune response provides a multitude of oligodendrocyte precursor cell differentiation-stimulating factors. Therefore, in theory, the main strategy for stimulating remyelination at early stages consists of removing, neutralizing, or overcoming early lesion-associated inhibitors of oligodendrocyte precursor cell differentiation.
At chronic stages a different set of factors mediates the inhibitory effects on oligodendrocyte precursor cell differentiation. Due to the lack of driving stimuli, in addition to neutralizing lesionassociated inhibitors, measures may also be necessary to activate oligodendrocyte precursor cells. These may consist of the administration of additional oligodendrocyte precursor cells stimulating factors or by altering the inflammatory environment, so as to replicate functions present during acute inflammation. However, prolonged exposure to a differentiation-inhibiting environment in chronic multiple sclerosis lesions potentially results in the loss of the intrinsic capability of oligodendrocyte precursor cells to differentiate, as suggested by an increased expression of TP30 (Nakahara et al., 2009) . Overall at present it therefore seems more feasible to aim at enhancing endogenous CNS remyelination at early stages of lesion development, e.g. after a relapse during the relapse-remitting phase of the disease, than during chronic progressive stages of multiple sclerosis.
Promoting CNS remyelination by modulation of the immune system
One possibility by which remyelination could potentially be facilitated is the modulation of the inflammatory environment. However, maintaining or even provoking an acute inflammatory milieu may well result in more harm than good. Possible beneficial roles of inflammatory cells for the process of remyelination include secretory functions (Kotter et al., 2005; Linker et al., 2009 ), the expression of major histocompatibility complex class II molecules related to the process of antigen presentation (Arnett et al., 2003) , and phagocytotic activity (Neumann et al., 2009) . Whereas the involvement of the innate immune system in the process of remyelination has received some attention in the past, the specific contribution of T and B cells remains to be determined .
Of particular interest is the ability of immunoglobulins to enhance remyelination. Most of the effective immunoglobulins appear to be of the IgM isotype and have been shown to be either low affinity polyreactive (being part of the natural autoreactive antibody repertoire), or high affinity monoclonal recognizing diverse epitopes on oligodendroglial cells (Wright et al., 2009) . Three general mechanisms that mediate antibody-induced CNS remyelination have been proposed (Ciric et al., 2004; Warrington and Rodriguez, 2008; Wright et al., 2009) . First, antibodies binding to glial cells are able to modulate intracellular changes related to cell function including stimulation of calcium fluxes and inducing antiapoptotic signalling in premyelinating oligodendrocytes (Warrington and Rodriguez, 2008; Wright et al., 2009) . In mice treated with this antibody type, caspase-3 activation and caspase gene expression were suppressed (Ciric et al., 2004; Howe et al., 2004) . A second mechanism by which antibodies could promote remyelination is by enhanced opsonization of myelin debris in the lesions, facilitating its removal by phagocytic cells (Neumann et al., 2009) . A third possible mechanism that has been suggested is by modulation of the immune response (Miller et al., 1996; Paz Soldan et al., 2003) . Encouraging results from the use of immunoglobulins in the Theiler's virus experimental model of CNS demyelination and early clinical trials reporting beneficial effects of intravenous immunoglobulin treatment with respect to clinical disability (Expanded Disability Status Scale) and relapse rate in multiple sclerosis (Fazekas et al., 1997; Achiron et al., 1998) prompted investigations into a potential repair promoting activity of this intervention. However, this could not be corroborated (Stangel and Hartung, 2002) and later studies failed to reproduce any beneficial effects on the course of multiple sclerosis (Hommes et al., 2004; Fazekas et al., 2008) . It is of note though, that the studies were designed to detect differences in disease activity and progression and lacked specific outcome measures reflecting regenerative processes such as remyelination. Furthermore, the therapeutic immunoglobulin preparations used almost exclusively contained IgG isotypes.
Stimulating oligodendrocyte precursor cell differentiation to enhance CNS remyelination
Very recently, a study reported beneficial effects of oestrogen receptor-b ligand on the functional outcome of experimental autoimmune encephalomyelitis, which at least in part seem to be related to enhanced remyelination (Crawford et al., 2010) . Previous studies have demonstrated that oestrogen receptor-b ligand does not influence the clinical onset of experimental autoimmune encephalomyelitis (Tiwari-Woodruff et al., 2007) . Although disease scores in treated animals did not appear to reach levels of controls, statistically significant differences were only detected following the peak of the disease. Oestrogen receptor-b ligand treatment in experimental autoimmune encephalomyelitis resulted in raised levels of mature oligodendrocytes and myelin basic protein and an increase in the thickness of myelin sheaths (Crawford et al., 2010) . These findings suggest that oestrogen receptor-b ligand is able to directly affect oligodendrocyte lineage cells. The notion that oestrogen receptor-b signalling regulates oligodendrocyte precursor cells functions is further supported by the expression of oestrogen receptors in oligodendrocyte lineage cells (Takao et al., 2004; Zhang et al., 2004) and the capability of oestrogens to enhance myelin membrane sheath formation and myelin basic protein expression in vitro (MarinHusstege et al., 2004) . Treatment with oestrogen receptor-b ligand did not alter the presence of immune cells, including T cells and macrophages, nor did it affect the expression of a variety of pro-inflammatory cytokines (Tiwari-Woodruff et al., 2007) . However, other functions of the innate immune system that play a role in the process of remyelination, including the phagocytosis of myelin debris and the secretion of growth factors (Kotter et al., 2005 have not been studied. As oestradiol is able to induce IGF-1 expression, a trophic factor for both oligodendrocyte precursor cells and differentiated oligodendrocytes (Masters et al., 1991; Barres et al., 1992; Ye and D'Ercole, 1999; Mason et al., 2000) secreted by macrophages in remyelinating lesions (Hinks and Franklin, 2000; Kotter et al., 2005) , immunomodulative effects of oestrogen receptor-b ligand cannot be ruled out. Thus, oestrogen receptor-b ligand-treatment is likely to beneficially modulate the course of experimental autoimmune encephalomyelitis via a combination of effects on the immune system as well as on oligodendrocyte lineage cells.
Overcoming lesion-associated inhibitors of oligodendrocyte precursor cell differentiation Alternative strategies to enhance CNS remyelination are based on overcoming the effects of oligodendrocyte precursor cell differentiation inhibitors by stimulating oligodendrocyte precursor cell differentiation, neutralizing the inhibitory effects or by a combination of both approaches. In this respect neutralizing early inhibitors present in the context of acute inflammation may hold more promise than neutralizing late stage inhibitors as the necessary stimulants provided in the context of acute inflammation are absent during chronic stages of multiple sclerosis lesions. Some of the mechanisms by which the inhibition of oligodendrocyte precursor cell differentiation by myelin associated inhibitors is regulated have recently been described. These consist in modulation of the Fyn-1-RhoA-ROCK cascade and in activation of PKC-signalling (Baer et al., 2009) . Small molecule or RNA interference-mediated inhibition of either cascade is able to neutralize the inhibitory effects of myelin associated inhibitors on oligodendrocyte precursor cell differentiation. Furthermore, co-incubation with pharmacological inhibitors of both cascades is able to increase the percentage of differentiating oligodendrocyte precursor cells to a greater extent than modulation of a single cascade.
These findings are clinically interesting because a variety of RHOA and PKC inhibitors are currently used in the clinic for the treatment of diseases other than multiple sclerosis.
In a recent study a mechanism related to inhibition of Fyn-1-RHOA-Rock signalling succeeded in promoting CNS remyelination, namely the inhibition of leucine rich repeat and Ig domain containing Nogo receptor interacting protein 1 (Lingo-1) (Mi et al., 2009) . Lingo-1 has initially been described as a co-receptor, which together with p75NTR (Wong et al., 2002) , mediates inhibitory signals from several myelin associated inhibitors, including NogoA, myelin associated glycoprotein, and oligodendrocyte myelin glycoprotein, on axon growth in a RhoA dependent manner (Mi et al., 2004) . However, none of these molecules negatively impacted on oligodendrocyte precursor cell differentiation (Syed et al., 2008) and thus identification of the molecular substrate in myelin responsible for the inhibition may open up further opportunities to promote remyelination.
Lingo-1 was subsequently identified as a key inhibitor of oligodendrocyte differentiation that exerts inhibitory effects on myelination during development via Fyn-1 and RhoA (Mi et al., 2005) . Furthermore, treatment with a Lingo-1 antagonist ameliorates outcome following myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis . More recently, it was formally demonstrated that treatment with Lingo-1 antagonist is able to promote remyelination by induction of oligodendrocyte precursor cell differentiation (Mi et al., 2009) . Although signalling via Lingo-1 in the context of myelin-associated inhibitors has not been formally proven, inhibiting Lingo-1 could potentially be considered as a strategy neutralizing early inhibitors in demyelinating lesions.
One of the down-stream targets of RHOA-Rock signalling that has been implicated in the inhibition of axon regeneration is Limk-1 (Lingor et al., 2007) . A recent study has also linked Limk-1 to a p57kip2-dependent control of oligodendrocyte precursor cell differentiation. Over-expression of p57kip2 in oligodendrocyte precursor cells can induce nuclear translocation of Limk-1 (Kremer et al., 2009 ) whereas sustained reduction of p57kip2 expression levels in oligodendroglial cells facilitates and promotes their differentiation. P57kip2 may therefore be regarded as an endogenous inhibitory regulator of oligodendrocyte precursor cell differentiation that needs to be suppressed before remyelination can occur. This view is further supported by the finding that in experimental autoimmune encephalomyelitis, down-regulation of p57kip2 expression levels correlates with the onset of remission. In contrast to these findings another group reported that small interfering RNA-dependent silencing of p57kip2 induces negative effects on the differentiation of oligodendrocyte precursor cells isolated from the optic nerve at P7-P8. In the same study the authors show that induction of p57kip2 oligodendrocytes is a component of the intracellular timer mechanism that controls the onset of oligodendrocyte precursor cell differentiation in the presence of mitogens and on specific differentiation cues (Dugas et al., 2007) . P57kip2 therefore appears to control oligodendrocyte differentiation at various levels and via several pathways.
Final remarks
In the present years our understanding of the interactions between the environment in multiple sclerosis lesions and the resident tissue stem/precursor cell population capable of regenerating myelinating oligodendrocytes has significantly increased. It has also become evident that the cellular and molecular environment of demyelinated multiple sclerosis lesions changes markedly over time according to the stage of the lesion. These changes are associated with changes in the presence of oligodendrocyte precursor cell inhibiting factors, which need to be taken into account when devising strategies that aim to promote remyelination in clinical disease.
By considering time-dependent changes in the inflammatory milieu and the composition of oligodendrocyte precursor cell differentiation inhibitors in multiple sclerosis lesions we arrive at a model that predicts that interventions targeted at neutralizing or overcoming early inhibitors are more likely to be effective than approaches targeting late stage inhibitors. Driven by the immune response, endogenous regenerative efforts are associated with acute stages of demyelination but at the same time are impaired by the presence of early inhibitors. Recent studies have demonstrated that clinically available drugs are able to neutralize and overcome oligodendrocyte precursor cell differentiation inhibitors Enhancing remyelination in disease in vitro (Baer et al., 2009) , and newly developed drugs, such as Lingo-1 inhibitors are currently being investigated in a clinical setting. Therefore, the implementation of remyelination-promoting strategies seems closer than ever.
